Allakos Accounts Payable Over Time
| ALLK Stock | USD 1.01 0.12 13.48% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Allakos Performance and Allakos Correlation. Allakos |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allakos. If investors know Allakos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allakos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.03) | Return On Assets (0.49) | Return On Equity (1.22) |
The market value of Allakos is measured differently than its book value, which is the value of Allakos that is recorded on the company's balance sheet. Investors also form their own opinion of Allakos' value that differs from its market value or its book value, called intrinsic value, which is Allakos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allakos' market value can be influenced by many factors that don't directly affect Allakos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allakos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allakos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allakos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accounts Payable Analysis
Compare Allakos and related stocks such as Apellis Pharmaceuticals, Blueprint Medicines Corp, and Karuna Therapeutics Accounts Payable Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APLS | 353.9 K | 353.9 K | 353.9 K | 353.9 K | 751.5 K | 2.5 M | 2.5 M | 3.7 M | 10.3 M | 8.4 M | 8.5 M | 16.9 M | 37.3 M | 37.5 M | 39.4 M |
| BPMC | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 814 K | 2.5 M | 2.2 M | 3.7 M | 3.3 M | 4.8 M | 4.4 M | 8.3 M | 2.7 M | 4.7 M | 3.9 M |
| DAWN | 69 K | 69 K | 69 K | 69 K | 69 K | 69 K | 69 K | 69 K | 69 K | 69 K | 202 K | 1.7 M | 260 K | 2.6 M | 2.7 M |
| ATRA | 121 K | 121 K | 121 K | 606 K | 440 K | 1.4 M | 2.8 M | 14.7 M | 3.7 M | 8 M | 7.1 M | 17.4 M | 6.9 M | 3.7 M | 6.1 M |
| FATE | 2.1 M | 2.1 M | 2.5 M | 682 K | 645 K | 996 K | 934 K | 1.7 M | 4.2 M | 5.8 M | 6.3 M | 8.6 M | 8.3 M | 4.7 M | 4 M |
| SANA | 289 K | 289 K | 289 K | 289 K | 289 K | 289 K | 289 K | 289 K | 289 K | 0.0 | 2.3 M | 2.2 M | 2.9 M | 4.1 M | 2.1 M |
| CRBU | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.6 M | 4 M | 1.1 M | 3.1 M | 2.1 M |
| RCUS | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.8 M | 3.1 M | 4.7 M | 15.7 M | 10.3 M | 20 M | 17 M | 10.8 M |
| RARE | 342 K | 342 K | 1.2 M | 1.4 M | 4.9 M | 2.9 M | 5.4 M | 8.9 M | 12.3 M | 12.9 M | 12.9 M | 17.1 M | 43.3 M | 42.1 M | 44.2 M |
| CRNX | 340 K | 340 K | 340 K | 340 K | 340 K | 340 K | 340 K | 403 K | 1.5 M | 5.5 M | 3.5 M | 3.4 M | 6.9 M | 6.5 M | 3.9 M |
| ARVN | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 596.5 K | 2.8 M | 4.6 M | 7.1 M | 31.3 M | 5.7 M | 17.8 M | 9.8 M |
| RVMD | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 5.2 M | 11.4 M | 12.6 M | 14.1 M | 21.3 M | 61.8 M | 64.9 M |
| KURA | 2.9 K | 2.9 K | 1.9 K | 350 | 360 K | 1.8 M | 1.4 M | 1.5 M | 4.1 M | 3.5 M | 2.8 M | 3.2 M | 1.5 M | 2.3 M | 1.9 M |
| NXTC | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 2.5 M | 1.9 M | 3.9 M | 1.9 M | 4.3 M | 2.3 M | 2.8 M |
| CTMX | 930 K | 930 K | 930 K | 930 K | 1.9 M | 4.7 M | 6.6 M | 4.2 M | 5.1 M | 4.2 M | 3 M | 2.8 M | 2.8 M | 1.5 M | 2.7 M |
| SPRO | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.1 M | 3.5 M | 3.6 M | 4.1 M | 1.2 M | 1.1 M | 617 K | 1.4 M | 1.6 M |
| ASMB | 4.1 M | 2.3 M | 1.8 M | 2.6 M | 907.6 K | 1.4 M | 2.4 M | 2.1 M | 3.7 M | 1.7 M | 4.6 M | 2.7 M | 2.5 M | 461 K | 437.9 K |
| ALLO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.3 M | 9.2 M | 10.4 M | 10.3 M | 13.9 M | 5.9 M | 9.7 M |
| HRTX | 300 K | 1 M | 1.9 M | 1.3 M | 3.4 M | 3.3 M | 7.9 M | 18.9 M | 17.1 M | 2.8 M | 525 K | 3.8 M | 3.2 M | 3.2 M | 3.2 M |
| ANNX | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.3 M | 2.4 M | 3.7 M | 11.2 M | 7.4 M | 5.5 M | 5.2 M |
| SGMO | 300 K | 4.1 M | 3 M | 3 M | 5.5 M | 3.9 M | 2.6 M | 16 K | 3.4 M | 6.7 M | 12.6 M | 9.8 M | 22.4 M | 15.3 M | 16 M |
Allakos and related stocks such as Apellis Pharmaceuticals, Blueprint Medicines Corp, and Karuna Therapeutics Accounts Payable description
An accounting item on the balance sheet that represents Allakos obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Allakos are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.My Equities
My Current Equities and Potential Positions
| Allakos | ALLK |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.01
Check out Allakos Performance and Allakos Correlation. For more information on how to buy Allakos Stock please use our How to buy in Allakos Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Allakos technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.